Evidence map›Paper›PMID 24288525›Full record

ArticlePPAR research2013

Polymorphisms in PPAR Genes (PPARD, PPARG, and PPARGC1A) and the Risk of Chronic Kidney Disease in Japanese: Cross-Sectional Data from the J-MICC Study.

Asahi Hishida, Kenji Wakai, Mariko Naito, Takashi Tamura, Sayo Kawai, Nobuyuki Hamajima, Isao Oze, Takeshi Imaizumi, Tanvir Chowdhury Turin, Sadao Suzuki and 7 more

Open access · goldAbstract read
In one paragraph

Article in PPAR research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Molecular Mechanisms of Cadmium-Induced Toxicity and Its Modification.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis.American journal of physiology. Renal physiology · 2016
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 2 countries.

Asahi HishidaDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan ; Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
Kenji Wakai
Mariko Naito
Takashi Tamura
Sayo Kawai
Nobuyuki Hamajima
Isao Oze
Takeshi Imaizumi
Tanvir Chowdhury Turin
Sadao Suzuki
Motahare Kheradmand
Haruo Mikami
Keizo Ohnaka
Yoshiyuki Watanabe
Kokichi Arisawa
Michiaki Kubo
Hideo Tanaka
Nagoya University · JPAichi Cancer Center · JPChiba Cancer Center · JPKagoshima University · JPKyoto Prefectural University of Medicine · JPKyushu University · JPNagoya City University · JPRIKEN Center for Integrative Medical Sciences · JPSaga University · JPShiga University of Medical Science · JPTokushima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is well known as a strong risk factor for both end stage renal disease and cardiovascular disease. To clarify the association of polymorphisms in the PPAR genes (PPARD, PPARG, and PPARGC1A) with the risk of CKD in Japanese, we examined this association among the Japanese subjects using the cross-sectional data of J-MICC (Japan Multi-Institutional Collaborative Cohort) Study. The subjects for this analysis were 3,285 men and women, aged 35-69 years, selected from J-MICC Study participants; genotyping was conducted by multiplex polymerase chain reaction-based Invader assay. The prevalence of CKD was determined for CKD stages 3-5 (defined as eGFR < 60 ml/min/1.73 m(2)). Participants with CKD accounted for 17.3% of the study population. When those with PPARD T-842C T/T were defined as reference, those with PPARD T-842C T/C and C/C demonstrated the OR for CKD of 1.26 (95%CI 1.04-1.53) and 1.31 (95%CI 0.83-2.06), respectively. There were no significant associations between the polymorphisms in other PPAR genes and the risk of CKD. The present study found a significantly increased risk of CKD in those with the C allele of PPARD T-842C, which may suggest the possibility of personalized risk estimation of this life-limiting disease in the near future.

Identifiers

PMID24288525
PMCPMC3830885
OpenAlexW2099404095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.